Clinical Trial of N-acetylcysteine Versus Placebo Efficacy in the Cannabis Withdrawal

• Status: Terminated
• Trial end date: 2015-02-01
• Target enrollment: 0
• Participant gender: All

Summary

The primary purpose is to assess the efficacy in human of N-acetylcysteine versus placebo during 4 weeks in cannabis withdrawal.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Assistance Publique - Hôpitaux de Paris
• Treatments: Acetylcysteine; N-monoacetylcystine

Criteria

Inclusion Criteria:

• > 18 year old

• Not pregnant or breast feeding

• Cannabis abuse or dependence diagnosis (DSM-IV)

• Acceptance of the trial and consent signed, validated by ethic committee

• Patient affiliated to social insurance care

Exclusion Criteria:

• Contraindication to N-acetylcystein : allergic to N-acetylcystein, severe allergic illness, PHENYLCETONURIA, lactose intolerance, gastro-duodenal ulcer.

• Severe somatic disease not stabilized : diabetes, epilepsia, recent myocardial infarcts, asthma.

• Severe mental disease not stabilized : schizophrenia.